Novel Therapies for Acromegaly

Overview

Journal Endocr Connect

Specialty Endocrinology

Date 2021 Jan 12

PMID 33434151

Citations 5

Authors

Bernardo Maia

Leandro Kasuki

Monica R Gadelha

Affiliations

Soon will be listed here.

Abstract

Acromegaly is a systemic disease associated with increased morbidity and mortality. Most of these comorbidities can be prevented or delayed with adequate disease treatment. Although three modalities of treatment (surgery, medical treatment, and radiotherapy) are available and new drugs were approved in the last decades, there are still some patients that maintain disease activity despite treatment. Therefore, there is a need for novel therapies for acromegaly and for that purpose new formulations of currently used drugs and also new drugs are currently under study. In this review, we summarize the novel therapies for acromegaly.

Citing Articles

Secondary diabetes mellitus in acromegaly: Case report and literature review.

Wang J, Zhang Z, Shi Y, Wang W, Hu Y, Chen Z Medicine (Baltimore). 2024; 103(39):e39847.

PMID: 39331882 PMC: 11441941. DOI: 10.1097/MD.0000000000039847.

New Treatments for Acromegaly in Development.

Gadelha M, Gadelha A, Kasuki L J Clin Endocrinol Metab. 2023; 109(4):e1323-e1327.

PMID: 37757837 PMC: 10940255. DOI: 10.1210/clinem/dgad568.

Clinical Management of Acromegaly: Therapeutic Frontiers and New Perspectives for Somatostatin Receptor Ligands (SRLs).

Brunetti A, Antonini S, Saladino A, Lavezzi E, Zampetti B, Cozzi R Medicina (Kaunas). 2022; 58(6).

PMID: 35744057 PMC: 9228014. DOI: 10.3390/medicina58060794.

Prevalence of comorbidities and concomitant medication use in acromegaly: analysis of real-world data from the United States.

Fleseriu M, Barkan A, Del Pilar Schneider M, Darhi Y, de Pierrefeu A, Ribeiro-Oliveira Jr A Pituitary. 2022; 25(2):296-307.

PMID: 34973139 PMC: 8894179. DOI: 10.1007/s11102-021-01198-5.

O-GlcNAcylation Is Essential for Rapid Pomc Expression and Cell Proliferation in Corticotropic Tumor Cells.

Massman L, Pereckas M, Zwagerman N, Olivier-Van Stichelen S Endocrinology. 2021; 162(12).

PMID: 34418053 PMC: 8482966. DOI: 10.1210/endocr/bqab178.

References

Sandret L, Maison P, Chanson P . Place of cabergoline in acromegaly: a meta-analysis. J Clin Endocrinol Metab. 2011; 96(5):1327-35. DOI: 10.1210/jc.2010-2443. View

Park S, Ku C, Moon J, Kim E, Kim S, Lee E . Age- and Sex-Specific Differences as Predictors of Surgical Remission Among Patients With Acromegaly. J Clin Endocrinol Metab. 2017; 103(3):909-916. DOI: 10.1210/jc.2017-01844. View

Bernabeu I, Alvarez-Escola C, Paniagua A, Lucas T, Pavon I, Cabezas-Agricola J . Pegvisomant and cabergoline combination therapy in acromegaly. Pituitary. 2012; 16(1):101-8. DOI: 10.1007/s11102-012-0382-z. View

Franck S, Broer L, van der Lely A, Kamenicky P, Bernabeu I, Malchiodi E . The Effect of the Exon-3-Deleted Growth Hormone Receptor on Pegvisomant-Treated Acromegaly: A Systematic Review and Meta-Analysis. Neuroendocrinology. 2016; 105(2):131-140. PMC: 5637298. DOI: 10.1159/000448844. View

Chiloiro S, Bima C, Tartaglione T, Giampietro A, Gessi M, Lauretti L . Pasireotide and Pegvisomant Combination Treatment in Acromegaly Resistant to Second-Line Therapies: A Longitudinal Study. J Clin Endocrinol Metab. 2019; 104(11):5478-5482. DOI: 10.1210/jc.2019-00825. View

Raverot G, Burman P, McCormack A, Heaney A, Petersenn S, Popovic V . European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas. Eur J Endocrinol. 2017; 178(1):G1-G24. DOI: 10.1530/EJE-17-0796. View

Tuvia S, Pelled D, Marom K, Salama P, Levin-Arama M, Karmeli I . A novel suspension formulation enhances intestinal absorption of macromolecules via transient and reversible transport mechanisms. Pharm Res. 2014; 31(8):2010-21. PMC: 4153969. DOI: 10.1007/s11095-014-1303-9. View

Kenakin T . Signaling bias in drug discovery. Expert Opin Drug Discov. 2017; 12(4):321-333. DOI: 10.1080/17460441.2017.1297417. View

Colao A, Auriemma R, Pivonello R, Kasuki L, Gadelha M . Interpreting biochemical control response rates with first-generation somatostatin analogues in acromegaly. Pituitary. 2015; 19(3):235-47. PMC: 4858561. DOI: 10.1007/s11102-015-0684-z. View

10.

Schofl C, Franz H, Grussendorf M, Honegger J, Jaursch-Hancke C, Mayr B . Long-term outcome in patients with acromegaly: analysis of 1344 patients from the German Acromegaly Register. Eur J Endocrinol. 2012; 168(1):39-47. DOI: 10.1530/EJE-12-0602. View

11.

Dorward N . Endocrine outcomes in endoscopic pituitary surgery: a literature review. Acta Neurochir (Wien). 2010; 152(8):1275-9. DOI: 10.1007/s00701-010-0649-y. View

12.

Melmed S, Bronstein M, Chanson P, Klibanski A, Casanueva F, Wass J . A Consensus Statement on acromegaly therapeutic outcomes. Nat Rev Endocrinol. 2018; 14(9):552-561. PMC: 7136157. DOI: 10.1038/s41574-018-0058-5. View

13.

Trainer P, Drake W, Katznelson L, Freda P, Lely A, Dimaraki E . Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med. 2000; 342(16):1171-7. DOI: 10.1056/NEJM200004203421604. View

14.

Kasuki L, Machado E, Ogino L, Alves Coelho M, Dos Santos Silva C, Wildemberg L . Experience with pegvisomant treatment in acromegaly in a single Brazilian tertiary reference center: efficacy, safety and predictors of response. Arch Endocrinol Metab. 2016; 60(5):479-485. PMC: 10118639. DOI: 10.1590/2359-3997000000210. View

15.

Katznelson L, Laws Jr E, Melmed S, Molitch M, Murad M, Utz A . Acromegaly: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2014; 99(11):3933-51. DOI: 10.1210/jc.2014-2700. View

16.

Tachas G, Lofthouse S, Wraight C, Baker B, Sioufi N, Jarres R . A GH receptor antisense oligonucleotide inhibits hepatic GH receptor expression, IGF-I production and body weight gain in normal mice. J Endocrinol. 2006; 189(1):147-54. DOI: 10.1677/joe.1.06553. View

17.

Samson S, Nachtigall L, Fleseriu M, Gordon M, Bolanowski M, Labadzhyan A . Maintenance of Acromegaly Control in Patients Switching From Injectable Somatostatin Receptor Ligands to Oral Octreotide. J Clin Endocrinol Metab. 2020; 105(10). PMC: 7470473. DOI: 10.1210/clinem/dgaa526. View

18.

Bollerslev J, Heck A, Olarescu N . MANAGEMENT OF ENDOCRINE DISEASE: Individualised management of acromegaly. Eur J Endocrinol. 2019; 181(2):R57-R71. DOI: 10.1530/EJE-19-0124. View

19.

Dias N, Stein C . Antisense oligonucleotides: basic concepts and mechanisms. Mol Cancer Ther. 2002; 1(5):347-55. View

20.

Tuvia S, Atsmon J, Teichman S, Katz S, Salama P, Pelled D . Oral octreotide absorption in human subjects: comparable pharmacokinetics to parenteral octreotide and effective growth hormone suppression. J Clin Endocrinol Metab. 2012; 97(7):2362-9. DOI: 10.1210/jc.2012-1179. View